The North America Bispecific Antibodies Market would witness market growth of 39.6% CAGR during the forecast period (2023-2030).
Bispecific antibodies (BsAbs), which may bind to two separate antigens or two different epitopes on the same antigen, are developing to increase the specificity and potency of antibodies. Bispecific antibodies produce superior outcomes with fewer adverse effects during low-cost treatment. Bispecific antibody sales are predicted to increase due to their potential therapeutic benefit against multiple diseases simultaneously. These are used to treat various illnesses, including infectious diseases, cardiovascular diseases, allergies, ocular issues, autoimmune and inflammatory disorders, and organ transplant rejection.
Six BsAbs, including Catumaxomab, the first approved BsAb, have been given FDA and/or EMA approval for cancer immunotherapy as of 2022. Hundreds of additional BsAbs are undergoing research, and the market is anticipated to expand in the coming years. As a result, major pharmaceutical corporations are becoming increasingly interested in researching and funding this promising immunotherapy. Because of their efficacy in oncology, BsAbs are also being investigated for the treatment of uncommon diseases, ophthalmic disorders, infections, autoimmune disorders, and other diseases.
The rising prevalence of autoimmune disorders in Canada is also responsible for the growing demand for bispecific antibodies. 19.3% of Canadians who were 15 years of age or older reported having arthritis in 2017 (or around 5.7 million persons), according to Statistics Canada. The prevalence of this chronic illness was 16.0% in men and 22.4% in women. With an increasing emphasis on creating cutting-edge bispecific antibody platforms and technologies, Canada is another significant market for North American antibodies. Many academic institutions and biotechnology firms are engaged in the research and development of bispecific antibody medicines in the nation. Therefore, the region presents lucrative growth potential for the market.
The US market dominated the North America Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $26,163.4 million by 2030. The Canada market is exhibiting a CAGR of 42.7% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 41.5% during (2023 - 2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Bispecific Antibodies Market is Projected to reach USD 80.2 Billion by 2030, at a CAGR of 40.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Cancer
- Inflammatory & Autoimmune Disorder
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Bispecific Antibodies Market, by Indication
1.4.2 North America Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. North America Bispecific Antibodies Market by Indication
4.1 North America Cancer Market by Country
4.2 North America Inflammatory & Autoimmune Disorder Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Bispecific Antibodies Market by Country
5.1 US Bispecific Antibodies Market
5.1.1 US Bispecific Antibodies Market by Indication
5.2 Canada Bispecific Antibodies Market
5.2.1 Canada Bispecific Antibodies Market by Indication
5.3 Mexico Bispecific Antibodies Market
5.3.1 Mexico Bispecific Antibodies Market by Indication
5.4 Rest of North America Bispecific Antibodies Market
5.4.1 Rest of North America Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 North America Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 2 North America Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bispecific Antibodies Market
TABLE 4 Trials and Approvals – Bispecific Antibodies Market
TABLE 5 Acquisition and Mergers– Bispecific Antibodies Market
TABLE 6 North America Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 7 North America Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 8 North America Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 North America Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 North America Inflammatory & Autoimmune Disorder Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Inflammatory & Autoimmune Disorder Market by Country, 2023 - 2030, USD Million
TABLE 12 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 13 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 14 North America Bispecific Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 15 North America Bispecific Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 16 US Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 17 US Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 18 US Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 19 US Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 20 Canada Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 21 Canada Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 22 Canada Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 23 Canada Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 24 Mexico Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 25 Mexico Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 26 Mexico Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 27 Mexico Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 28 Rest of North America Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 29 Rest of North America Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 30 Rest of North America Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 31 Rest of North America Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 32 Key Information – Amgen, Inc.
TABLE 33 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 34 Key Information – Pfizer, Inc.
TABLE 35 Key Information – Akeso, Inc.
TABLE 36 Key information –Johnson & Johnson
TABLE 37 key Information – Taisho Pharmaceuticals Holding Co., Ltd.
TABLE 38 Key Information – Immunocore Holdings plc
TABLE 39 Key Information – GlaxoSmithKline PLC
TABLE 40 Key Information – Novartis AG
TABLE 41 Key Information – Allergan PLC
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
FIG 5 North America Bispecific Antibodies Market share by Indication, 2022
FIG 6 North America Bispecific Antibodies Market share by Indication, 2030
FIG 7 North America Bispecific Antibodies Market by Indication, 2019 - 2030, USD Million
FIG 8 North America Bispecific Antibodies Market share by Country, 2022
FIG 9 North America Bispecific Antibodies Market share by Country, 2030
FIG 10 North America Bispecific Antibodies Market by Country, 2019 - 2030, USD Million
FIG 11 Recent strategies and developments: Johnson & Johnson